Furthermore, cells treated with TGFβ before the transfer in the adopted therapy of cancer appear to be more effective, as one might expect, if the TGFβ treatment selectively eliminated SLECs and thus enriched the population for cells not able to respond as effectively to TGFβ [28]. Here, TGFB1 is linked to cancer.